Adriamycin-induced Nephropathy

Adriamycin-induced Nephropathy Model of Chronic Kidney Disease


RenaSci offers the adriamycin-induced nephropathy mouse model of chronic kidney disease (CKD). Adriamycin is a drug used in cancer chemotherapy. When given to animals it produces glomerular sclerosis and changes in tubulo-interstitial histology that mirror the pathological changes seen in human CKD. These changes are robust and reproducible and occur within days following intravenous administration of adriamycin. They are accompanied by impaired kidney function as shown by marked increases in urinary albumin excretion and the urinary/creatinine ratio.

Increased Urinary Albumin and Albumin/Creatinine Ratio in the Adriamycin-induced Nephropathy Model

Effect of Adriamycin on Kidney Histology


Kidney sections were processed by Periodic Acid Schiff staining (counterstained with haematoxylin) for blinded assessment by a pathologist (PathCelerate) using light microscopy. The glomerulosclerosis score represents the average score of ten representative glomeruli per section.

The adriamycin-induced nephropathy model has been validated by the angiotensin-converting enzyme inhibitor, enalapril, which is used for the treatment of both CKD and diabetic nephropathy. Enalapril improved the plasma, urinary and histological end-points of renal disease and also the tubulo-interstitial kidney fibrosis, which develops in these animals.

The model can be used to evaluate the efficacy of new drugs to treat chronic kidney disease. It complements our existing models of diabetic nephropathy and has the advantage that it is of much shorter duration as it does not depend on the development or progression of diabetes.

Please contact us for further information about the adriamycin-induced nephropathy mouse model of chronic kidney disease.